KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 1st Annual H.C. Wainwright Hereditary Angioedema Conference, set for July 20, 2022, at 12:00 p.m. ET. CEO Andrew Crockett will engage in an expert panel on oral treatments for hereditary angioedema (HAE) at 11:00 a.m. ET. Webcasts of the presentation and panel will be available on the company's website, with an audio archive accessible for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for HAE and diabetic macular edema.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 1^st Annual H.C. Wainwright Hereditary Angioedema Conference (virtual) on Wednesday, July 20, 2022 at 12:00 p.m. ET. KalVista CEO Andrew Crockett will also participate as part of an expert panel discussing oral treatments for hereditary angioedema (HAE) at 11:00 a.m. ET.

Live webcasts of the presentation and panel will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

For more information on the KVD824 HAE prophylaxis Phase 2 KOMPLETE study, please visit www.kompletestudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for sebetralstat, KVD824 and other candidates in development, the ability of sebetralstat, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005532/en/

KalVista Pharmaceuticals, Inc.

Jarrod Aldom

Vice President, Corporate Communications

(201) 705-0254

jarrod.aldom@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

What is KalVista Pharmaceuticals presenting at the H.C. Wainwright Conference?

KalVista Pharmaceuticals will present on July 20, 2022, with CEO Andrew Crockett participating in a panel discussion on oral treatments for hereditary angioedema.

When is KalVista Pharmaceuticals’ presentation scheduled?

The presentation is scheduled for July 20, 2022, at 12:00 p.m. ET.

Where can I watch KalVista Pharmaceuticals’ presentation?

Live webcasts will be available on KalVista Pharmaceuticals' website, and an audio archive will be accessible for 30 days following the event.

What is the focus of KalVista Pharmaceuticals?

KalVista Pharmaceuticals focuses on the discovery and development of oral, small molecule protease inhibitors for hereditary angioedema and diabetic macular edema.

What are KalVista's key products under development?

KalVista is developing sebetralstat for acute HAE attacks and KVD824 for HAE prophylaxis, along with an oral Factor XIIa inhibitor program.